Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Elobixibat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 11,801Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dr Reddy's launches medication to treat chronic constipation
    Dr Reddy's launches medication to treat chronic constipation

    29 Oct 2024

    // PRESS RELEASE

    https://www.drreddys.com/cms/cms/sites/default/files/2024-10/Bixibat-%20PR-%20Final%20-%2028th%20Oct%202024.pdf

    PRESS RELEASE
    29 Oct 2024
    Share Share
    Another blow to NASH,disappointing trial results spell end for darkhorse Albireo
    Another blow to NASH,disappointing trial results spell end for darkhorse Albireo

    20 Aug 2020

    // Jason Mast ENDPTS

    https://endpts.com/another-blow-to-nash-disappointing-trial-results-spell-end-for-darkhorse-player-albireo/

    Jason Mast ENDPTS
    20 Aug 2020
    Share Share
    Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH
    Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH

    18 Aug 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/08/18/2080294/0/en/Albireo-Reports-Topline-Results-from-Phase-2-Trial-of-Elobixibat-in-NAFLD-NASH.html

    GLOBENEWSWIRE
    18 Aug 2020
    Share Share